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WHAT THE AMISH CAN TELL US ABOUT. . . CHOLESTASIS
Bull LN, van Eijk MJT, Pawlikowska L, DeYoung JA, Juijn JA,
Liao M, Klomp LWJ, Lomri N, Berger R, Scharschmidt BF,
Knisely AS, Houwen RHJ, Freimer NB. A gene encoding a
P-type ATPase is mutated in two forms of hereditary cholesta-
sis. Nat Genet 1998;18:219-224. (Reprinted with permission.)
ABSTRACT
Cholestasis, or impaired bile flow, is an important but
poorly understood manifestation of liver disease. Two
clinically distinct forms of inherited cholestasis, benign
recurrent intrahepatic cholestasis (BRIC) and progressive
familial intrahepatic cholestasis type 1 (PFIC1), were previ-
ously mapped to 18q21. Haplotype analysis narrowed the
candidate region for both diseases to the same interval of
less than 1 cM, in which we identified a gene mutated in
BRIC and PFIC1 patients. This gene (called FIC1) is the
first identified human member of a recently described
subfamily of P-type ATPases; ATP-dependent aminophospho-
lipid transport is the previously described function of
members of this subfamily. FIC1 is expressed in several
epithelial tissues and, surprisingly, more strongly in small
intestine than in liver. Its protein product is likely to play an
essential role in enterohepatic circulation of bile acids;
further characterization of FIC1 will facilitate understand-
ing of normal bile formation and cholestasis.
de Vree JML, Jacquemin E, Sturm E, Cresteil D, Bosma PJ,
Aten J, Deleuze J-F, Desrochers M, Burdelski M, Bernard O, Oude
Elferink RPJ, Hadchouel M. Mutations in the MDR3 gene
cause progressive familial intrahepatic cholestasis. Proc Natl
Acad Sci U S A 1998;95:282-287. (Reprinted with permission.)
ABSTRACT
Class III multidrug resistance (MDR) P-glycoproteins
(P-gp), mdr2 in mice and MDR3 in man, mediate the
translocation of phosphatidylcholine across the canalicular
membrane of the hepatocyte. Mice with a disrupted mdr2
gene completely lack biliary phospholipid excretion and
develop progressive liver disease, characterized histologi-
cally by portal inflammation, proliferation of the bile duct
epithelium, and fibrosis. This disease phenotype is very
similar to a subtype of progressive familial intrahepatic
cholestasis, hallmarked by a high serum g-glutamyltransfer-
ase (g-GT) activity. We report immunohistochemistry for
MDR3 P-gp, reverse transcription-coupled PCR sequence
analysis, and genomic DNA analysis of MDR3 from two
progressive familial intrahepatic cholestasis patients with
high serum g-GT. Canalicular staining for MDR3 P-gp was
negative in liver tissue of both patients. Reverse transcrip-
tion-coupled PCR sequencing of the first patient’s sequence
demonstrated a homozygous 7-bp deletion, starting at
codon 132, which results in a frameshift and introduces a
stop codon 29 codons downstream. The second patient is
homozygous for a nonsense mutation in codon 957 (C - T)
that introduces a stop codon (TGA). Our results demon-
strate that mutations in the human MDR3 gene lead to
progressive familial intrahepatic cholestasis with high se-
rum g-GT. The histopathological picture in these patients is
very similar to that in the corresponding mdr2 (2/2)
mouse, in which mdr2 P-gp deficiency induces complete
absence of phospholipid in bile.
COMMENTS
Progressive familial intrahepatic cholestasis (PFIC) is the
name given to a group of autosomal recessive disorders in
which cholestasis develops in early infancy and progresses to
end-stage liver disease before adulthood.1,2 Patients with
PFIC type 1 (PFIC1), or Byler disease, named for the
extended Amish kindred in which it was first described,3
exhibit disproportionately low serum g-glutamyl transpepti-
dase (GGTP) and cholesterol levels for the degree of cholesta-
sis, along with a bland intracanalicular cholestasis by light
microscopy and coarsely granular bile on transmission elec-
tron microscopy.4 By using material from the original Byler
kindred, the gene responsible for PFIC1 was mapped to
chromosome 18q21-22.5 This same region had been linked
earlier to benign recurrent intrahepatic cholestasis (BRIC), a
disease characterized by episodic attacks of jaundice and
pruritus but without progressive liver disease6; this suggested
that the two phenotypes are allelic variants of the same
disease. In contrast, there is a second group of patients with
PFIC who exhibit high serum GGTP levels and bile duct
proliferation along with portal inflammatory infiltrates on
liver histology.7 These changes resemble those that have been
observed following disruption of the mdr2 gene, the mouse
homolog of human MDR3, which encodes a canalicular
P-glycoprotein required for biliary phospholipid secretion.8
In one patient with this second type of PFIC, MDR3
messenger RNA was undetectable and in another phospho-
lipid in bile was markedly reduced.9 The biochemical features
of PFIC had been previously linked to defects in either bile
salt synthesis10 or bile salt secretion.11 Total biliary bile acids
were markedly reduced (1.1 6 1.4 mmol/L) in seven patients
with PFIC compared with values in eight control patients
with other cholestatic diseases (88.9 6 83.2 mmol/L).11
Strikingly low percentages of chenodeoxycholic acid were
observed in gallbladder bile from the PFIC patients.11
In this context, two independent groups have now defined
the molecular defects underlying various forms of PFIC. The
gene mutated in PFIC1 and BRIC patients, termed FIC1 (for
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familial intrahepatic cholestasis 1), exhibits significant simi-
larity to a subfamily of P-type ATPase genes that encode
putative aminophospholipid transporters.12 Five mutations
in FIC1 were identified in patients with PFIC1, including two
missense mutations that replace amino acids that are highly
conserved in P-type ATPases, suggesting that these are critical
to normal protein structure and/or function. In patients with
BRIC, two different mutations were identified, including a
missense mutation and a small deletion, that are in less highly
conserved regions of the gene. This finding provides a
potential explanation for the differences among the clinical
manifestations of BRIC and PFIC1, because the BRIC muta-
tions are expected to have less of an effect on FIC1 structure
and function. A surprising finding was preferential expres-
sion of FIC1 in the small intestine, consistent with a role for
this gene product in the intestinal handling of bile acids.
Although malabsorption and diarrhea have been described in
patients with PFIC1,3,13 the clinical manifestations of PFIC1
and BRIC led many to suspect that the defect underlying
these disorders would be localized to the liver. Furthermore,
FIC1 was identified in a wide variety of tissues, including
sites not associated with bile acid handling, such as pancreas
and stomach. This finding suggests that FIC1 may have a
general role in absorptive and secretory processes. Other
members of the subfamily to which FIC1 belongs are believed
to maintain an asymmetric distribution of phospholipids in
membranes by the transport of aminophospholipids from
outer to inner leaflets.12 Clearly, additional studies are re-
quired to determine how FIC1 functions and how mutations
cause disease. Nevertheless, the identification of FIC1 as the
defect in PFIC1 and BRIC represents a significant shift in our
understanding of the pathophysiology of cholestatic liver
disease.
In the second study, two children with PFIC and high
serum GGTP levels were found to have mutations in MDR3.
Canalicular staining for MDR3 P-glycoprotein was absent in
liver biopsy specimens in both children. As a control, staining
of the canalicular membranes with antibodies directed against
MDR1 P-glycoprotein and MRP2/cmoat, the canalicular trans-
porter involved in the secretion of nonbile acid organic
anions, was normal. Two mutations were identified using
reverse transcription-polymerase chain reaction; a seven-
nucleotide deletion and a single nonsense mutation, both
resulting in the introduction of stop codons and truncated
messenger RNA. This finding is another milestone in our
understanding of cholestatic liver disease. By starting with a
gene, in this case mdr2 in the mouse, and determining its
function to define a phenotype, it represents a fundamentally
different but equally successful approach to that pursued in
the first study in which a defined phenotype was used to
identify a defective gene.
Another locus for PFIC has been recently identified on
chromosome 2q24 and designated PFIC2.14 This locus corre-
sponds to that of the human sister P-glycoprotein (SPGP)
gene.15 The protein product of this liver-specific gene is
abundantly expressed on the canalicular membrane.16 Rat
spgp expressed in Xenopus oocytes and in membrane vesicles
isolated from transfected Sf9 insect cells was recently found
to mediate adenosine triphosphate–dependent bile acid trans-
port.17 Furthermore, taurochenodeoxycholate, the concentra-
tion of which is strikingly low in gallbladder bile from PFIC
patients,11 was the preferred substrate for spgp.17 These
findings suggest that spgp is a canalicular bile acid trans-
porter and that mutations of the human liver SPGP gene are
responsible for PFIC type 2. In three patients with PFIC and
normal serum GGTP levels, SPGP messenger RNA was
normal but SPGP was undetectable on the canalicular mem-
brane by immunohistochemistry,18 consistent with a traffick-
ing defect. To date, 15 mutations in SPGP have been
identified in patients with PFIC2 (Richard Thompson, Depart-
ment of Pediatrics, University College London Medical School,
London, UK, personal communication).
In summary, the molecular basis for all forms of PFIC may
now have been identified. However, the implications of these
findings may extend far beyond a mere understanding of a
group of relatively rare inherited cholestatic disorders. Lith1,
a gene that has been identified as a determinant of cholesterol
gallstone susceptibility in inbred mice, co-localizes with
spgp.19 Thus, a potential link has been established between
canalicular bile salt secretion and cholesterol gallstone forma-
tion. Further characterization of the function of the gene
products of FIC1, MDR3, and SPGP holds the promise of
even more advances in bridging the gap between the bench
and the bedside.
RICHARD H. MOSELEY, M.D.
VA Medical Center and
University of Michigan Medical Center
Ann Arbor, MI
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HEREDITARY HEMOCHROMATOSIS—SOMETIMES HAVING
A REAL COMPLEX CAN BE A GOOD THING
Feder JN, Penny DM, Irrinki A, Lee VK, Lebron JA, Watson N,
Tsuchihashi Z, Sigal E, Bjorkman PJ, Schatzman RC. The
hemochromatosis gene product complexes with the transfer-
rin receptor and lowers its affinity for ligand binding. Proc
Natl Acad Sci U S A 1998;95:1472-1477. (Reprinted with
permission.)
ABSTRACT
We recently reported the positional cloning of a candi-
date gene for hereditary hemochromatosis called HFE. The
gene product, a member of the major histocompatibility
complex class I-like family, was found to have a mutation,
Cys-282 Tyr (C282Y), in 85% of patient chromosomes. This
mutation eliminates the ability of HFE to associate with
b2-microglobulin (b2m) and prevents cell-surface expres-
sion. A second mutation that has no effect on b2m associa-
tion, H63D, was found in eight out of nine patients
heterozygous for the C282Y mutant. In this report, we
demonstrate in cultured 293 cells overexpressing wild-type
or mutant HFE proteins that both the wild-type and H63D
HFE proteins form stable complexes with the transferrin
receptor (TfR). The C282Y mutation nearly completely
prevents the association of the mutant HFE protein with the
TfR. Studies on cell-associated transferrin at 377C suggest
that the overexpressed wild-type HFE protein decreases the
affinity of the TfR for transferrin. The overexpressed H63D
protein does not have this effect, providing the first direct
evidence for a functional consequence of the H63D muta-
tion. Addition of soluble wild-type HFE/b2m heterodimers
to cultured cells also decreased the apparent affinity of the
TfR for its ligand under steady-state conditions, both in 293
cells and in HeLa cells. Furthermore, at 47C, the added
soluble complex of HFE/b2m inhibited binding of transfer-
rin to HeLa cell TfR in a concentration-dependent manner.
Scatchard plots of these data indicate that the added
heterodimer substantially reduced the affinity of TfR for
transferrin. These results establish a molecular link be-
tween HFE and a key protein involved in iron transport, the
TfR, and raise the possibility that alterations in this
regulatory mechanism may play a role in the pathogenesis
of hereditary hemochromatosis.
COMMENTS
In recent years, many disease genes have been successfully
cloned by establishing a linkage between the gene and
markers from known locations in the genome. One of the
virtues of a positional cloning approach to identify a disease-
related gene is that information about the function of the
gene is not required for success. As long as patients with the
disease can be unequivocally identified, the discovery of
mutations within a candidate gene in affected individuals but
not in healthy individuals should be sufficient to prove that
the gene is correct. Positional cloning has identified many
disease genes; however, there are several situations in which a
disease gene bore no resemblance to genes of known function
and, thus, provided little insight into pathogenesis. In other
instances, a disease gene resembled known genes but the
relationship between the gene and the disease process was
initially obscure. Such was the case for hereditary hemochro-
matosis, whose gene named HFE was cloned in 1996.1
HFE is similar in sequence to major histocompatibility
complex class I genes, a family of polymorphic integral
membrane proteins that associate noncovalently with a 12-kd
protein b2 microglobulin (b2m). Within the endoplasmic
reticulum, class I molecules capture and bind peptides
derived from proteolytic digestion of intracellular proteins.
Once peptide is bound to a class I molecule, the complex
exits the endoplasmic reticulum and moves to the cell surface
where peptides from viral proteins that are expressed in an
infected cell can be recognized as foreign and can target the
cell for destruction by T-lymphocytes. There is another group
of major histocompatibility complex class I proteins that are
atypical in that they have maintained the basic structure of
class I molecules, but have other biological roles, as in the
case of CD1 and the neonatal Fc receptor.2
Although the mechanism by which an abnormality in a
class I–like gene would lead to iron overload was initially
quite obscure, the observation fit well with previous data that
mice homozygous for a targeted disruption in the b2m gene
develop iron overload (presumably as a consequence of loss
of b2m and, therefore, loss of the functional HFE-b2m
complex).3 Subsequently, it has been shown that mice homo-
zygous for a targeted disruption of HFE also develop iron
overload similar to that in hereditary hemochromatosis.
Together these findings confirm that functional absence of
HFE leads to hemochromatosis.4
Because loss of HFE results in iron overload, it is reason-
able to expect that HFE interacts in some fashion with
proteins of iron metabolism. To attempt to identify potential
HFE-interacting proteins, Feder et al. analyzed immunopre-
cipitates from cells in which HFE was overexpressed. Initially,
cell-surface proteins were labeled with N-hydroxysuccin-
amide, and HFE was immunoprecipitated with antibodies to
the native HFE C-terminus or to an epitope tag inserted in the
overexpressed HFE. In these experiments, HFE and b2m were
coimmunoprecipitated as expected, but in addition, other
proteins were identified at approximately 100 and 200 kd.
When known proteins of iron metabolism were considered, it
became apparent that the 100- and 200-kd bands were quite
similar to those seen in immunoprecipitations of the transfer-
rin receptor (TfR), which can migrate as a dimer as well as in
a monomeric form of approximately 100 kd. The identity of
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